AIM: The aim of the retrospective study was to develop a planning class solution for prostate intensity-modulated radiotherapy (IMRT) that achieved target and organs-at-risk (OAR) doses within acceptable departmental protocol criteria using the Monaco treatment planning system (Elekta-CMS Software, MO, USA). BACKGROUND: Advances in radiation therapy technology have led to a re-evaluation of work practices. Class solutions have the potential to produce highly conformal plans in a time-efficient manner. MATERIALS AND METHODS: Using data from intermediate and high risk prostate cancer patients, a stepwise quality improvement model was employed. Stage 1 involved the development of a broadly based treatment template developed across 10 patients. Stage 2 involved template refinement and clinical audit (n = 20); Stage 3, template review (n = 50) and Stage 4 an assessment of a revised template against the actual treatment plan involving 72 patients. RESULTS: The computer algorithm that comprised the Stage 4 template met clinical treatment criteria for 82% of patients. Minor template changes were required for a further 13% of patients. Major changes were required in 4%; one patient could not be assessed. The average calculation time was 13 min and involved seven mouse clicks by the planner. Thus, the new template met treatment criteria or required only minor changes in 95% of prostate patients; this is an encouraging result suggesting improvements in planning efficiency and consistency. CONCLUSION: It is feasible to develop a class solution for prostate IMRT using a stepwise quality improvement model which delivers clinically acceptable plans in the great majority of prostate cases.
AIM: The aim of the retrospective study was to develop a planning class solution for prostate intensity-modulated radiotherapy (IMRT) that achieved target and organs-at-risk (OAR) doses within acceptable departmental protocol criteria using the Monaco treatment planning system (Elekta-CMS Software, MO, USA). BACKGROUND: Advances in radiation therapy technology have led to a re-evaluation of work practices. Class solutions have the potential to produce highly conformal plans in a time-efficient manner. MATERIALS AND METHODS: Using data from intermediate and high risk prostate cancerpatients, a stepwise quality improvement model was employed. Stage 1 involved the development of a broadly based treatment template developed across 10 patients. Stage 2 involved template refinement and clinical audit (n = 20); Stage 3, template review (n = 50) and Stage 4 an assessment of a revised template against the actual treatment plan involving 72 patients. RESULTS: The computer algorithm that comprised the Stage 4 template met clinical treatment criteria for 82% of patients. Minor template changes were required for a further 13% of patients. Major changes were required in 4%; one patient could not be assessed. The average calculation time was 13 min and involved seven mouse clicks by the planner. Thus, the new template met treatment criteria or required only minor changes in 95% of prostate patients; this is an encouraging result suggesting improvements in planning efficiency and consistency. CONCLUSION: It is feasible to develop a class solution for prostate IMRT using a stepwise quality improvement model which delivers clinically acceptable plans in the great majority of prostate cases.
Authors: Shea William Wilcox; Noel J Aherne; Craig Steven McLachlan; Michael J McKay; Andrew J Last; Thomas P Shakespeare Journal: J Med Imaging Radiat Oncol Date: 2015-01-15 Impact factor: 1.735
Authors: Anna N Steer; Noel J Aherne; Karen Gorzynska; Matthew Hoffman; Andrew Last; Jacques Hill; Thomas P Shakespeare Journal: Int J Radiat Oncol Biol Phys Date: 2013-04-19 Impact factor: 7.038
Authors: Patrick J Horsley; Noel J Aherne; Grace V Edwards; Linus C Benjamin; Shea W Wilcox; Craig S McLachlan; Hassan Assareh; Richard Welshman; Michael J McKay; Thomas P Shakespeare Journal: Asia Pac J Clin Oncol Date: 2014-09-16 Impact factor: 2.601
Authors: Shea W Wilcox; Noel J Aherne; Linus C Benjamin; Bosco Wu; Thomaz de Campos Silva; Craig S McLachlan; Michael J McKay; Andrew J Last; Thomas P Shakespeare Journal: Onco Targets Ther Date: 2014-08-30 Impact factor: 4.147